Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
1.
New Microbiol ; 46(4): 390-394, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-38252050

RESUMEN

At 23 days of life a neonate presented to the emergency room with crying and decreased oral intake. His parents were positive to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), but he turned out negative. After one week he was admitted to NICU (neonatal intensive care unit) for respiratory failure, and nasopharyngeal swab (PCR test: polymerase chain reaction test) was positive for SARS-CoV-2. On examination the child had fever, tachy-dyspnea, reduced oxygen saturation, tachycardia, abdominal distension and tenderness, irritability and hypertonia. Blood exam showed respiratory acidosis, lymphocytopenia, hypoalbuminemia and coagulopathy; CRP (C reactive protein), procalcitonin, D-dimer, ferritin and NT-proBNP (N-terminal prohormone of brain natriuretic peptide) were elevated. Chest X-ray revealed bilateral interstitial infi ltration and abdomen ultrasound a thin fl uid effusion; echocardiography was normal. SARS-CoV-2 PCR tests on CSF (cerebrospinal fluid) and stool were also positive. He was started on non-invasive intermittent positive pressure respiratory ventilation, treated with antibiotic therapy, methylprednisolone, intravenous immunoglobulins, and antiplatelet therapy. Rapid clinical improvement was seen with remission of fever after eight days. The child complicated with bacterial super-infection presenting as pleural empyema. As presented in our case, it is not always easy to differentiate between severe forms of COVID-19 and MIS-C. Due to the rarity of these presentations in neonates, multicentric collaboration is needed to identify the specifi c characteristics of the two forms, better defi ne diagnostic criteria, and treatment options.


Asunto(s)
COVID-19 , Niño , Masculino , Recién Nacido , Humanos , COVID-19/diagnóstico , SARS-CoV-2 , Síndrome de Respuesta Inflamatoria Sistémica
3.
Front Biosci (Schol Ed) ; 14(4): 28, 2022 10 14.
Artículo en Inglés | MEDLINE | ID: mdl-36575838

RESUMEN

BACKGROUND: Since the beginning of COVID-19 pandemic, an increase in new diagnoses and pediatric hospital admission for anorexia nervosa (AN) or atypical AN in adolescents have been reported, suggesting an adverse effect of COVID-19 on youth mental health. We hypothesized possible differences in prevalence of hospitalization and/or disease severity, related to socio-economic status and/or ethnicity. METHODS: Retrospectively, patients were divided into two subgroups and compared according to the date of first hospital admission: "pre SARS-COV2 era" group (n. 45, 8th March 2016-8th March 2020) and "SARS-COV2 era" group (n. 43, 9th March 2020-8th March 2022). RESULTS: During the two years of the SARS-COV2 era, we reported an increase in hospital admission incidence more than doubled respect to the "pre-SARS-COV2 era". The "SARS-COV2 era group" showed a more rapid weight loss (p = 0.005), a minor duration of weight loss from lifetime maximum to admission (p = 0.019) and needed most frequently treatments with intravenous fluids (p < 0.0001), oral dietetic supplements (p <0.001) and enteral nutrition by nasogastric tube (p = 0.002). The same group presented higher prevalence of psychiatric comorbidities (63% vs. 22%, p < 0.0001) and required most frequently treatments with psychotropic drugs (56% vs. 24%, p = 0.002). We found higher family socioeconomic status (SES) in our patients with AN in both the periods and we did not find a shift in social class distribution over time. CONCLUSIONS: Our study confirms a significant increase in incidence of hospitalization and of psychiatric comorbidity in the pediatric population with AN during the second year of COVID-19 pandemic, regardless of SES or ethnic background. Further studies are needed to understand potential mechanisms that during COVID-19 pandemic trigger eating disorder symptoms.


Asunto(s)
Anorexia Nerviosa , COVID-19 , Humanos , Adolescente , Niño , COVID-19/epidemiología , Anorexia Nerviosa/epidemiología , Anorexia Nerviosa/terapia , Anorexia Nerviosa/psicología , Estudios Retrospectivos , Pandemias , ARN Viral , SARS-CoV-2 , Comorbilidad , Pérdida de Peso
4.
New Microbiol ; 45(3): 223-226, 2022 07.
Artículo en Inglés | MEDLINE | ID: mdl-35920879

RESUMEN

Neonatal sepsis is a systemic condition characterized by haemodynamic changes and other clinical manifestations due to a presence of pathogenic microorganisms (bacteria, viruses, or fungi) in nor- mally sterile fluid that occurs in an infant younger than 90 days old. Neonatal sepsis may be divided into two types: early-onset neonatal sepsis (EOS) and late-onset neonatal sepsis (LOS). Gram-posi- tive microorganisms are the etiological agents in 62% of EOS, and in 43% of the total the identified microorganism is GBS. Gram-negative microorganisms comprise 37% of the etiological agents of EOS, of which 29% are caused by Escherichia coli. ESBL-producing Enterobacteriaceae represent a major worldwide threat among drug-resistant bacteria in both hospital and community settings. ESBLs are often located on large plasmids that also harbour genes resistant to other antimicrobial classes, resulting in multidrug-resistant isolates. Plasmid-encoded ESBLs of the CTX-M-type are increasingly reported worldwide in Gram-negative rods and now account for most of the ESBLs found in Enterobacteriaceae. We present one case of EOS by Multi Drug Resistant (MDR) and ESBL producing E. coli (CTX-M gene) in a neonate born to a mother recently immigrated from Africa. Maternal blood culture grew the same bacteria.


Asunto(s)
Infecciones por Escherichia coli , Sepsis Neonatal , Antibacterianos/uso terapéutico , Enterobacteriaceae/genética , Escherichia coli/genética , Infecciones por Escherichia coli/microbiología , Humanos , Recién Nacido , Sepsis Neonatal/tratamiento farmacológico , beta-Lactamasas/genética
7.
Infez Med ; 26(2): 122-125, 2018 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-29932083

RESUMEN

Little is known about the effectiveness of antibiotic prophylaxis for prevention of surgical site infections (SSIs) in paediatric abdominopelvic surgical oncology. A retrospective analysis was performed upon the incidence of SSIs in children receiving a 24-hour antibiotic prophylaxis with cefazolin for abdominopelvic oncological surgery. In all, 145 patients (57% females) with a median age of 4 years underwent surgical procedures for abdominopelvic tumours. No SSIs were detected, despite the various risk factors known to be associated with their occurrence (such as pre- and post- surgical chemotherapy, long hospitalization, intensive care unit admission and drain placement). Cefazolin prophylaxis seems to be safe and effective in preventing SSIs in children undergoing abdominopelvic surgery for oncological diseases.


Asunto(s)
Neoplasias Abdominales/cirugía , Antibacterianos/uso terapéutico , Profilaxis Antibiótica , Cefazolina/uso terapéutico , Neoplasias Pélvicas/cirugía , Infección de la Herida Quirúrgica/prevención & control , Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Incidencia , Lactante , Masculino , Estudios Retrospectivos , Infección de la Herida Quirúrgica/epidemiología , Adulto Joven
8.
Infez Med ; 25(4): 358-361, 2017 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-29286016

RESUMEN

The use of sugar for treating wounds which are difficult to heal and positive to resistant pathogens has already been documented. The authors describe the successful treatment by direct instillation of granular sugar in the antibiotic-resistant infected surgical site wound of a child with sarcoma. Sugar instillation in the extended spectrum beta-lactamase (ESBL)-producing Enterobacter cloacae positive wound, in addition to systemic treatment with meropenem and levofloxacin, allowed culture negativization in six days and complete wound healing in 30 days. These results make the use of sugar an attractive option for wounds which are difficult to treat, even in an immunocompromised child.


Asunto(s)
Enterobacter cloacae/efectos de los fármacos , Infecciones por Enterobacteriaceae/terapia , Neurilemoma/complicaciones , Neoplasias de los Tejidos Blandos/complicaciones , Sacarosa/uso terapéutico , Infección de la Herida Quirúrgica/terapia , Administración Tópica , Niño , Terapia Combinada , Farmacorresistencia Bacteriana Múltiple , Infecciones por Enterobacteriaceae/tratamiento farmacológico , Humanos , Huésped Inmunocomprometido , Levofloxacino/uso terapéutico , Masculino , Meropenem , Neurilemoma/cirugía , Neoplasias de los Tejidos Blandos/cirugía , Sacarosa/administración & dosificación , Infección de la Herida Quirúrgica/tratamiento farmacológico , Tienamicinas/uso terapéutico , Cicatrización de Heridas
9.
Pediatr Hematol Oncol ; 34(1): 24-28, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-28085529

RESUMEN

Acute acalculous cholecystitis (AAC) is an inflammation of the gallbladder without the presence of gallstones. In children with malignancies or chemotherapy-induced neutropenia, AAC is very rare. Clinical diagnosis of AAC remains difficult in this patient population but an early recognition followed by an appropriate intervention may confer a benefit. Only three pediatric patients with underlying hematological malignancies whose clinical treatment course was complicated by the development of AAC have been described. We describe a neutropenic pediatric patient who developed AAC following chemotherapy for acute T-cell acute lymphoblastic leukemia (T-ALL), which was successfully managed with conservative treatment. ABBREVIATIONS: AAC: Acute acalculous cholecystitis; T-ALL: T-cell acute lymphoblastic leukemia; TPN: Total parenteral nutrition.


Asunto(s)
Colecistitis Alitiásica/terapia , Neutropenia/terapia , Leucemia-Linfoma Linfoblástico de Células T Precursoras/tratamiento farmacológico , Colecistitis Alitiásica/inducido químicamente , Colecistitis Alitiásica/diagnóstico , Niño , Humanos , Masculino , Neutropenia/inducido químicamente , Neutropenia/diagnóstico
10.
J Pediatr Surg ; 52(4): 593-597, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27614809

RESUMEN

PURPOSE: Nontuberculous mycobacteria are uncommon cause of chronic cervicofacial lymphadenitis in healthy children. We describe clinical features and management strategies of cervicofacial nontuberculous mycobacterium lymphadenitis in a tertiary pediatric hospital. METHODS: Retrospective analysis of medical records of children discharged from 1992 to 2014 with a diagnosis of cervicofacial nontuberculous mycobacterium was made. Diagnosis certainty was based on microhistological investigations. Clinical stage was evaluated according to lymph node size and presence of fistulas. Successful therapy was defined by the regression of the lymph node enlargement (>75%) or complete surgical excision without relapse. RESULTS: Cervicofacial nontuberculous mycobacterium was diagnosed in 33 patients. Complete excision was performed in 73% of cases primarily observed in our hospital, while 83% of those referred from other hospitals required further surgical treatment. No case of relapse was observed after one year of follow-up. CONCLUSIONS: We recommend surgical approach as the first therapeutic option in the management of cervicofacial nontuberculous mycobacterium lymphadenitis. LEVELS OF EVIDENCE: Prognosis and Retrospective Study - Level II.


Asunto(s)
Escisión del Ganglio Linfático , Linfadenitis/cirugía , Infecciones por Mycobacterium no Tuberculosas/cirugía , Adolescente , Niño , Preescolar , Enfermedad Crónica , Femenino , Estudios de Seguimiento , Hospitales Pediátricos , Humanos , Lactante , Linfadenitis/diagnóstico , Masculino , Infecciones por Mycobacterium no Tuberculosas/diagnóstico , Cuello , Estudios Retrospectivos , Centros de Atención Terciaria , Resultado del Tratamiento
11.
New Microbiol ; 39(3): 232-234, 2016 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-27284990

RESUMEN

We report a case of primary intestinal infection due to filamentous fungi in an adolescent with Ewing sarcoma. The clinical picture was that of peritonitis secondary to intestinal perforation and the diagnosis was established only on histopathological bases. This condition is very rare, and only one case of primary intestinal mold infection in children with solid tumors has been reported in the literature, although more records can be found describing similar conditions in other cancer patient populations (i.e. adults with solid tumors or children with hematological malignancies or patients receiving hemopoietic stem cell transplant). Clinicians must be aware of this possibility since only an aggressive medical and surgical approach can improve patients' prognosis.


Asunto(s)
Enfermedades Intestinales/microbiología , Micosis/etiología , Sarcoma de Ewing/complicaciones , Adolescente , Niño , Resultado Fatal , Femenino , Humanos , Enfermedades Intestinales/etiología , Micosis/patología
12.
J Rheumatol ; 43(6): 1093-100, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-27036377

RESUMEN

OBJECTIVE: The aim of our study was to analyze the clinical and functional effect of the p.Q703K (p. Q705K, c. 2107C>A) variant of the NLRP3 gene in a population of patients screened for suspected cryopyrin-associated periodic syndrome (CAPS). METHODS: Since 2002, 580 patients underwent molecular analysis for NLRP3. Data on clinical presentation, response to treatment, and longterm followup were collected using a uniform questionnaire. The pattern of cytokine secretion after lipopolysaccharide stimulation from isolated monocytes was analyzed in 3 patients carrying the p.Q703K variant and 1 patient with a chronic infantile neurologic, cutaneous, articular syndrome phenotype carrying both the p.M406I and p.Q703K, and compared with 7 patients with CAPS with sure pathogenic variants and 6 healthy controls. RESULTS: The p.Q703K variant was found in 57 screened patients with an overall allelic frequency of 5%. The frequency in normal controls was 5.5%. Clinical data at the moment of molecular analysis and at followup were available in 36 patients. Two patients displayed additional mutations of NLRP3. The mean followup was 2.5 years. Thirteen patients (39%) had a final diagnosis different from the original suspicion of CAPS. The remaining 21 patients displayed a mild phenotype mainly characterized by recurrent episodes of urticarial rash and arthralgia. Only 8 patients were treated with anti-interleukin (IL)-1 treatment, with a complete response in 5 patients. The pattern of secretion of IL-1ß and other cytokines (IL-6 and IL-1 receptor antagonist) in patients did not display the aberrancies observed in patients with CAPS and was similar to that observed in healthy controls. CONCLUSION: The present study confirms the weak clinical and functional effect of the p.Q703K variant.


Asunto(s)
Artralgia/etiología , Síndromes Periódicos Asociados a Criopirina/diagnóstico , Exantema/etiología , Mutación , Proteína con Dominio Pirina 3 de la Familia NLR/genética , Fenotipo , Adolescente , Adulto , Artralgia/genética , Artralgia/metabolismo , Niño , Preescolar , Síndromes Periódicos Asociados a Criopirina/complicaciones , Síndromes Periódicos Asociados a Criopirina/genética , Citocinas/metabolismo , Exantema/genética , Exantema/metabolismo , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Monocitos/metabolismo , Adulto Joven
13.
BMJ Case Rep ; 20152015 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-25564584

RESUMEN

PURPOSE: To report a long-term follow-up of a young woman affected by cystic fibrosis (CF) with a residual retroperitoneal mass of neuroblastoma (NBL) after treatment. CASE REPORT: We reviewed the patient's database and analysed a 20-year follow-up by considering pulmonary exacerbation, nutritional condition, pulmonary function (forced expiratory volume in 1 s), microbiological data and residual retroperitoneal mass volume. We observed stable pulmonary and nutritional conditions. No variation was found in the residual retroperitoneal mass volume. DISCUSSION: We report this case of a patient with CF with previous NBL because such a long time of follow-up of a NBL with a stable retroperitoneal remaining tumour is uncommon and needs to be reported. Multidisciplinary management has been crucial in this case because of the presence of concomitant diseases and consequently, differential diagnosis challenges.


Asunto(s)
Carcinoma/cirugía , Fibrosis Quística/complicaciones , Hígado/patología , Neoplasias Primarias Secundarias/cirugía , Neuroblastoma/complicaciones , Neoplasias Retroperitoneales/complicaciones , Neoplasias de la Tiroides/cirugía , Carcinoma Papilar , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Hiperplasia/complicaciones , Hipotiroidismo/complicaciones , Recién Nacido , Neoplasia Residual , Neuroblastoma/terapia , Neoplasias Retroperitoneales/terapia , Cáncer Papilar Tiroideo , Factores de Tiempo , Adulto Joven
15.
J Chemother ; 27(5): 307-11, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24824366

RESUMEN

OBJECTIVES: To review the data available in literature about nebulized amphotericin B (AMB) in the treatment of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) and to report our experience in the use of this drug, with a particular therapeutic scheme. CASE REPORT: We used nebulized liposomal amphotericin B (L-AMB) in a patient affected by CF, complicated by ABPA. The previous combined treatment with oral steroids and azoles had no respiratory benefit and caused relevant side effects. Amphotericin B has always been well tolerated and permitted a slight steroid tapering. We also observed benefits in pulmonary function and laboratory tests. CONCLUSIONS: Few data are available in literature about the use of nebulized AMB in CF and there are no RCTs evaluating antifungals in CF-ABPA. In our opinion, the reported case suggests that nebulized L-AMB could represent a possible strategy in ABPA management in CF patients.


Asunto(s)
Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Aspergilosis Broncopulmonar Alérgica/tratamiento farmacológico , Aspergillus fumigatus/efectos de los fármacos , Fibrosis Quística/complicaciones , Adulto , Aspergilosis Broncopulmonar Alérgica/microbiología , Manejo de la Enfermedad , Humanos , Masculino , Adulto Joven
16.
Acta Radiol Short Rep ; 3(11): 2047981614549571, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25535572

RESUMEN

Anaplasma phagocytophilum, an obligate intracellular bacterium, is the causative agent of human granulocytic anaplasmosis (HGA), a tickborne infection usually manifesting as fever, malaise, cytopenia, spleen enlargement, and hepatitis. Herein, we report a case of a 14-year-old girl with HGA whose whole-body magnetic resonance imaging (MRI) disclosed an unusual picture characterized by small, widespread punctuate millimetric nodules, hypointense on T1-weighted and hyperintense on STIR sequences. This firstly reported finding may represent an alternative tool for identifying atypical infectious diseases.

17.
Ital J Pediatr ; 40: 98, 2014 Nov 26.
Artículo en Inglés | MEDLINE | ID: mdl-25425177

RESUMEN

Acute cerebellar ataxia (ACA) is a relatively common neurological disease in children. Most common types of ACA are acute post-infectious (APCA) and acute disseminated encephalomyelitis (ADEM). Less common but important causes include opsoclonus-myoclonus syndrome (OMS) and acute cerebellitis. Cerebellar neoplasms and acute hydrocephalus are additional causes of paediatric ataxia. APCA is the most common cause of ACA in children, comprising about 30-50% of total cases. This is a report about an immunocompetent 4-yrs-old male affected by APCA, due to co-infection by human herpesvirus-6 (HHV-6) and adenovirus, with symptoms mimicking myositis.


Asunto(s)
Infecciones por Adenoviridae/complicaciones , Adenoviridae , Ataxia Cerebelosa/etiología , Coinfección/complicaciones , Herpesvirus Humano 6 , Miositis/diagnóstico , Infecciones por Roseolovirus/complicaciones , Enfermedad Aguda , Infecciones por Adenoviridae/diagnóstico , Niño , Diagnóstico Diferencial , Humanos , Masculino , Infecciones por Roseolovirus/diagnóstico
19.
Pediatr Pulmonol ; 49(2): E10-2, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23401277

RESUMEN

Bacterial respiratory infections have an important impact on the development and progression of pulmonary disease in cystic fibrosis (CF). Viral infections are possible triggers of acute deterioration in the clinical status of CF patients. Macrophage activation syndrome (MAS) is a life-threatening complication of rheumatic disease characterized by pancytopenia, hepatitis, hyperferritinemia, coagulopathy, and neurologic symptoms. This syndrome is thought to be caused by the activation and uncontrolled proliferation of T lymphocytes and well-differentiated macrophages, leading to widespread hemophagocytosis and cytokine overproduction. Here, we report the case of a boy affected by CF who developed MAS triggered by pandemic H1N1 influenza; good clinical response was obtained through high dose prednisone treatment.


Asunto(s)
Fibrosis Quística/complicaciones , Subtipo H1N1 del Virus de la Influenza A , Gripe Humana/complicaciones , Síndrome de Activación Macrofágica/virología , Niño , Humanos , Subtipo H1N1 del Virus de la Influenza A/aislamiento & purificación , Gripe Humana/diagnóstico , Síndrome de Activación Macrofágica/diagnóstico , Masculino
20.
BMJ Case Rep ; 20132013 Apr 29.
Artículo en Inglés | MEDLINE | ID: mdl-23632183

RESUMEN

The aim of the paper is to report the case of a boy affected by cystic fibrosis, with non-ABPA-related recurrent wheezing and frequent pulmonary exacerbation during childhood, who had been  inhaling 7% NaCl+0.1% hyaluronic acid (HA) as a maintenance therapy. We reviewed patient database and, analysing a 7-year follow-up, considered pulmonary exacerbation, antibiotic and steroid courses, pulmonary function (forced expiratory volume in one second; FEV1) and microbiological data. After starting 7% NaCl+0.1% HA treatment, we observed a dramatic decrease of oral antibiotic need (0.55 courses/month during the pretreatment period against 0.10 courses/month in the treatment period), associated with a good initial recovery and a stability of FEV1. In our opinion this case could suggest an extended indication for inhaled 7% NaCl+0.1% HA use in CF, not only in patients who did not tolerate hypertonic saline, but also in patients with coexistent asthma-like symptoms.


Asunto(s)
Asma/tratamiento farmacológico , Fibrosis Quística/tratamiento farmacológico , Ácido Hialurónico/administración & dosificación , Solución Salina Hipertónica/administración & dosificación , Viscosuplementos/administración & dosificación , Adolescente , Asma/fisiopatología , Fibrosis Quística/fisiopatología , Humanos , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...